Σελίδα 1 από 30 Αποτελέσματα
Throughout this application, various publications are referenced. Full bibliographic citations for these publications are found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this
1. FIELD OF THE INVENTION
The invention relates to cationic ceramides, dihydro ceramides, their analogs and their derivatives. The invention also relates to methods of making the compounds and various uses of the compounds, such as the prevention and treatment of diseases associated with cell
BACKGROUND OF THE DISCLOSURE
Technical Field
The present disclosure relates to the field of cancer therapy using anti-angiogenic agents, not as anticancer therapeutics per se, but as chemosensitization agents--to make patients more sensitive to chemotherapy, thereby increasing the effect of
Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic
Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic
TECHNICAL AREA OF THE INVENTION
The invention relates to the area of cancer chemopreventative agents. More particularly, the invention relates to the area of screening assays for cancer chemopreventative agents.
BACKGROUND OF THE INVENTION
Because common epithelial cancers have resisted most
FIELD OF THE INVENTION
The invention relates to the area of regulation of intracellular signaling. More particularly, the invention relates to the regulation of human ceramide kinase activity to increase or decrease intracellular signaling.
BACKGROUND OF THE INVENTION
Human ceramide kinase
CROSS-REFERENCE TO RELATED APPLICATIONS
This patent application is related to co-pending U.S. patent application Ser. No. 12/485,546, titled "Compositions for inducing immune responses specific to Globo H and SSEA-3 and uses thereof in cancer treatment" filed Jun. 16, 2009, which claims priority to
TECHNICAL FIELD
This invention relates to hybridoma cell lines that produce monoclonal antibodies useful for the detection and treatment of human cancers.
BACKGROUND OF THE INVENTION
Dramatic changes in chemical composition, metabolism, and organization of cell-surface glycosphingolipids
REFERENCE TO RELATED APPLICATION
This application claims priority from U.S. Provisional Patent Application Ser. No. 61/484,496, filed May 10, 2011, the entire content of which is incorporated herein by reference.
FIELD OF THE INVENTION
The present invention relates generally to liposome compositions
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to novel polyethylene glycol (PEG) derivatized lipids, their method of preparation and their use in liposomes or other lipid-based carriers. More specifically, the present invention includes PEG-Ceramide lipids and
FIELD OF THE INVENTION
The present invention concerns the ceramide analog compounds of the general formula (I) specified below, their corresponding preparation process, and their use in the preparation of pharmaceutical formulations with an antitumor effect.
STATE OF THE ART
Ceramides are lipids
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 17, 2012, is named WAR00125.txt and is 5,303 bytes in size.
BACKGROUND OF THE
BACKGROUND OF THE INVENTION
Membrane sphingolipids have been shown to be biologically active and exert numerous regulatory effects on cellular functions including modulating cell growth and differentiation. Ceramides, found in high concentrations within the cell membrane, are a family of lipid
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 19, 2015, is named WAR-002.01_SL.txt and is 5,378 bytes in size.
BACKGROUND OF THE